Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 72

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 72
---
 during the course of a clinical trial; |

| ● | adding a sufficient number 
 of clinical trial sites;   |

| ● | obtaining sufficient product                                                                              
 supply of product candidate for use in preclinical studies or clinical trials from third-party suppliers; |

| ● | the FDA’s or the                                                                                                                
 applicable foreign regulatory agency’s findings of deficiencies or failure to approve the manufacturing processes or facilities 
 of third-party manufacturers upon which we rely; or                                                                             |

| ● | the approval policies or                                                                                                             
 regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data 
 insufficient for approval.                                                                                                           |

We may experience numerous
adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent our ability
to receive marketing approval or commercialize our product candidates, including:

| ● | we may receive feedback                                                                   
 from regulatory authorities that requires us to modify the design of our clinical trials; |

| ● | we may obtain a result                                                                                                           
 from preclinical studies such as a binder specificity study or a safety toxicology study that require us to modify the design of 
 our clinical trials, abandon our research efforts for product candidates, or result in delays;                                   |

| ● | clinical trials of our                                                                                                                 
 product candidates may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional 
 clinical trials or abandon our research efforts for our other product candidates;                                                      |

| ● | the number of patients                                                                                                           
 required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may 
 be slower than we anticipate or participants may drop out of our clinical trials at a higher rate than we anticipate;            |

| ● | our third-party contractors                                                                                                            
 may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient 
 product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at      
 all;                                                                                                                                   |

| ● | we or our investigators                                                                                                                    
 might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory 
 requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding         
 that the participants are being exposed to unacceptable health risks;                                                                      |

| ● | the cost of clinical trials                                  
 of our product candidates may be greater than we anticipate; |

| ● | the